Open AccessPenetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men
Author(s) -
Jade Ghosn,
MarieLaure Chaix,
Gilles Peytavin,
Elisabeth Rey,
Jean-Louis Bresson,
Cécile Goujard,
Christine Katlama,
JeanPaul Viard,
JeanMarc Tréluyer,
Christine Rouzioux
Publication year - 2004
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/00002030-200409240-00014
Subject(s) - enfuvirtide , efavirenz , tenofovir , virology , protease inhibitor (pharmacology) , penetration (warfare) , human immunodeficiency virus (hiv) , medicine , viral load , antiretroviral therapy , immunology , gp41 , antigen , epitope , operations research , engineering
One likely mechanism of virological failure is poor antiretroviral drug diffusion in sites of viral replication such as the genital tract. We measured antiretroviral drug concentrations in blood and semen in 13 HIV-infected men failing treatment. Enfuvirtide did not cross the blood-testis barrier, whereas tenofovir accumulated in semen. Unlike indinavir, semen concentrations of lopinavir, amprenavir, saquinavir and efavirenz were ineffective. These are worrying findings, because suboptimal semen drug concentrations may enhance the risk of sexually transmitted drug-resistant HIV variants.